Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if the combination of recombinant human growth
hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than
either drug alone (or no active therapy) for the treatment of fat accumulation in people with
HIV infection and insulin resistance.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)